Tiziana Life Sciences Plc Reports Additional Positive Phase 2a Clinical Study Results For Milciclib

  • Sep 04, 2019 BST
  • Team Kalkine

Tiziana Life Sciences Plc (AIM: TILS), has announced an additional positive Phase 2a clinical study results, which was conducted to evaluate the safety, tolerability and anti-tumor activity of Milciclib in Sorafenib-resistant patients

The data from the study exhibited the impressive clinical activity of Milciclib monotherapy in patients with advanced Sorafenib-resistant or intolerant patients with unresectable or metastatic hepatocellular carcinoma.

On 4th September 2019, at the time of writing, GMT 08:13 AM, TILS shares were trading at GBX 60.00, up by 12.00 points or 25.00% against the previous day closing price.

With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities. 

Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?

Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.

We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.

To know more about these dividend stocks, click here

CLICK HERE FOR YOUR FREE REPORT!
   
x
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK